Biosimilars Market worth $70.79 billion by 2036
The report "Biosimilars Market by Drug Class (mAbs [Adalimumab, Infliximab, Rituximab, Trastuzumab], GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2036", is projected to grow from USD 37.39 billion in 2026 and to reach USD 70.79 billion by 2036, at a Compound Annual Growth Rate (CAGR) of 6.6% during the forecast period.
Browse 380 market data Tables and 60 Figures spread through 402 Pages and in-depth TOC on "Biosimilars Market by Drug Class (mAbs [Adalimumab, Infliximab, Rituximab, Trastuzumab], GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2036"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html
Several key factors are driving the expansion of the biosimilars market, including the increasing prevalence of chronic and complex diseases, rising utilization of biologic therapies, and the expiration of patents and regulatory exclusivity for several high-revenue reference biologics. Governments, payers, and healthcare systems are increasingly promoting biosimilars as cost-effective alternatives to originator biologics to reduce treatment expenditure and improve patient access to advanced therapies. In parallel, improvements in analytical characterization, cell-line development, bioprocessing, and manufacturing technologies are enabling companies to develop and commercialize biosimilars more efficiently. Greater regulatory clarity, accumulated real-world evidence, increasing physician confidence, and broader acceptance of switching from reference biologics are also supporting market penetration. The emergence of biosimilars for high-value monoclonal antibodies, including therapies used in oncology and immunology, is expected to create significant opportunities for manufacturers as major biologics lose exclusivity over the forecast period. Companies such as Celltrion, Samsung Bioepis, Bio-Thera Solutions, and Alteogen are among the players expanding their pipelines toward next-generation high-value biosimilar opportunities.
However, intensifying pricing pressure and increasing competitive density are expected to remain major challenges for market growth and profitability. As multiple biosimilars enter the same molecule market, manufacturers increasingly compete through discounts, rebates, tenders, formulary positioning, and contracting, resulting in progressive erosion of average selling prices.
“By indication, oncology segment accounted for largest market share in 2025”
The rising global incidence of cancer, combined with the substantial cost of biologic therapies, has made oncology the leading therapeutic area within the biosimilars market. Biosimilars provide more affordable alternatives to reference biologics, supporting broader patient access to essential cancer treatments and helping healthcare systems manage escalating treatment costs. Growing investment in oncology R&D has further strengthened the role of biosimilars as a cost-containment strategy. Key biosimilars used in oncology include trastuzumab, bevacizumab, rituximab, filgrastim, epoetin alfa, and denosumab. Continued regulatory approvals, expanding clinical adoption, and increasing collaboration among pharmaceutical stakeholders are expected to further support the growth of the oncology segment of the market.
“By drug class, monoclonal antibodies segment held largest market share in 2025 and will exhibit highest CAGR from 2026 to 2036”
Rituximab, Infliximab, Adalimumab, Trastuzumab, Pembrolizumab, Dupilumab, Ustekinumab, Risankizumab, Daratumumab, Nivolumab, and other monoclonal antibodies (mAbs) are widely used biologic therapies for the treatment of autoimmune diseases, cancers, chronic conditions, and certain infectious diseases. Developed using recombinant DNA (rDNA) technology, these therapies are designed to selectively target specific antigens or cellular receptors, enabling high therapeutic specificity and efficacy. The growing availability of biosimilars for established mAbs is expected to reduce treatment costs, improve patient access, and increase the affordability of biologic therapies. Furthermore, the expiration of patents and exclusivity periods for several high-value mAbs is expected to encourage biosimilar entry and intensify market competition, resulting in greater pricing pressure and increased investment in mAb biosimilar development. With their broad applications across oncology, immunology, and other therapeutic areas, mAb biosimilars are expected to play an increasingly important role in expanding access to advanced biologic treatments and shaping the future healthcare landscape.
“By region. Europe accounted for largest market share in 2025”
Europe has emerged as the leading contributor to the biosimilar market, driven by pro-biosimilar governmental policies, heightened investments in research and development, and an increasing disease burden. Key suppliers in this arena include France, Italy, Spain, Germany, and the UK. In 2026, the European Union marks the 20th anniversary of its biosimilar regulatory framework. Over the past two decades, the European Medicines Agency (EMA) has evaluated 180 biosimilar applications, issuing positive opinions for 160 products. This extensive regulatory experience highlights the EU’s longstanding leadership in establishing a robust and science-based framework for the development, evaluation, and approval of biosimilars globally.
Key Players
Key players in the biosimilars market include Sandoz Group AG (Switzerland), Pfizer Inc. (US), Amgen Inc. (US), Celltrion Inc. (South Korea), Biocon Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), Stada Arzneimittel AG (Germany), Boehringer Ingelheim International GmbH (Germany), Samsung Bioepis Co., Ltd. (South Korea), Amneal Pharmaceuticals, Inc. (US), Bio-Thera Solutions, Ltd. (China), Aprogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), and Alvotech (Iceland).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Biosimilars Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
